Clinical Diagnostics Testing
Granger Genetics is located in Richmond , Virginia. The company evolved after an asset purchase in 2016. The original company became independently owned in 2011 from Bostwick Labs and continued an existing model of “everything to everybody” providing clinical testing services and a strong contract research organization. Senior management determined that the company’s “best self” would be the focus on clinical laboratory testing and molecular biology research. Granger Genetics evolved out of this restructuring, giving the company a better focus on its services, a more robust research program and fresh forward thinking leadership to drive the company with new diagnostic products and services. Here at Granger in our clinical laboratories, our #1 goal and commitment is to patient safety and quality. We are a CLIA certified laboratory to perform high complexity diagnostic testing. We are constantly seeking solutions to specific medical concerns brought to our attention. Providing the medical community with personalized, quality testing options is what sets Granger Genetics apart from the competition. We no longer want to be “everything to everybody”- we want to be your choice for your patients in personalized medicine.
David G. Bostwick, M.D., M.B.A.
Granger Genetics presented the results from a recently completed studies at the Fall 2016 Symposium on Advanced Wound Care held this month at Caesar’s Palace in Las Vegas, NV. Dr. William Budd, Vice-President of Science and Technology for Granger Genetics presented an abstract entitled “Use of Molecular Identification to Determine Organisms in Wounds.” According to[…]
Granger Diagnostics today announced immediate availability of the first commercially-available next-generation sequencing test for wounds and infections. This test ensures discovery of ALL bacteria, ALL fungi, ALL parasites, and select viruses. The test requires only a simple swab of the wound or infected area. David G. Bostwick, MD, Chief Medical Officer, described Granger Diagnostics’ advanced[…]
Antimicrobial Resistance Genes and Modeling of Treatment Failure in Bacterial Vaginosis: Clinical Study of 289 Symptomatic Women
3/10/2016 Dr. David Bostwick and the team at AIBiotech recently published the above titled paper in the Journal of Medical Microbiology. This study is the second paper to come out of work to understand the role of bacterial flora in development of bacterial vaginosis (BV). This study evaluated the presence of anti-microbial resistance genes in[…]
American International Biotechnology, LLC Introduces GynecoloGene; The World’s First Commercially-Available Metagenomics Next-Generation Sequencing Test for Women Suffering from Bacterial Vaginosis
RICHMOND, VIRGINIA Oct. 8, 2015 — Today, American International Biotechnology, LLC presented results from GynecoloGene, the world’s first commercially-available next-generation sequencing test for bacterial vaginosis at the XXI FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. In a presentation entitled: “The Microbiome and Women’s Health”,” David G. Bostwick, MD, Chief Medical Officer,[…]